Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial

NCT05494580 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05494580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05494580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Completed
Start date
September 22, 2022
Completion date
January 31, 2026
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinosarcoma, ovarian cancer, ovarian carcinoma, platinum-resistant ovarian cancer, primary peritoneal cancer